Stock Comparison

JNJ vs WVE

Johnson & Johnson vs WAVE Life Sciences Ltd

The Verdict

WVE takes this one.

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Winner

WVE

WAVE Life Sciences Ltd

6.9

out of 10

Solid Pick

Head-to-Head

$557.1B

Market Cap

$1.1B

26.5

P/E Ratio

N/A

21.8%

Profit Margin

-255.7%

26.3%

Return on Equity

-55.7%

0.6

Debt-to-Equity

N/A

Conservative

Overall Risk

Aggressive

1.0

DVR Score

6.9

The Deep Dive

JNJ1.0/10

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Full JNJ Analysis

WVE6.9/10

WAVE Life Sciences continues to present a high-risk, high-reward profile, with its score remaining consistent due to no new material changes since the last analysis, although Q1 2026 EPS beat estimates. The company's 10x growth potential hinges on the successful progression and potential accelerated approval of WVE-006 for alpha-1 antitrypsin deficiency (AATD), supported by recent positive RestorA...

Full WVE Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.